8/24/2020 7:14:18 AM
Trevena Initiates Proof-of-concept Study For TRV027 In COVID-19 Patients
6/2/2020 7:13:11 AM
Trevena Announces Collaboration With Imperial College London To Evaluate TRV027 In COVID-19 Patients
3/12/2020 7:14:29 AM
Trevena Q4 Net Loss Attributable $6.4 Mln Or $0.07 Per Share
3/5/2020 7:19:00 AM
Trevena Reports FDA Set PDUFA Date Of August 7, 2020 For Oliceridine
2/10/2020 7:04:39 AM
Trevena Resubmits NDA To FDA For IV Oliceridine
12/23/2019 7:09:47 AM
Trevena Begins Proof-of-Concept Study For TRV734 For Potential Treatment Of Opioid Use Disorder
6/27/2019 7:14:09 AM
Trevena Appoints Barry Shin As CFO
3/13/2019 7:18:54 AM
Trevena Q4 Net Loss Attributable $8.0 Mln Or $0.10 Per Share